Second purchase in two weeks brings total to 3,000 shares; strategy chief also adds to stake

SK Biopharm President and CEO Lee Dong-hoon speaks at a press conference at the Westin Josun Hotel in Jung-gu, Seoul. [SK Biopharm]
SK Biopharm President and CEO Lee Dong-hoon speaks at a press conference at the Westin Josun Hotel in Jung-gu, Seoul. [SK Biopharm]

Key executives at SK Biopharm have made a series of open-market share purchases, signaling their commitment to responsible management and shareholder value.

SK Biopharm disclosed Tuesday that President and CEO Lee Dong-hoon bought an additional 1,000 shares on Friday. The average acquisition price was 78,800 won ($59) per share, bringing the total purchase to about 79 million won.

Lee had previously bought 2,000 shares on Aug. 27, and returned to the market roughly two weeks later, bringing his total recent share purchases to 3,000.

On the same day, Chief Strategy Officer Yoo Chang-ho also acquired 500 additional shares at an average price of 79,087 won per share. Yoo had likewise purchased 500 shares on Aug. 27, and expanded his stake further with this latest purchase.

The company said the executives' decision to invest their own funds in rapid succession reflected strong confidence in the company's medium- to long-term growth strategy, as well as a firm commitment to defending corporate value and practicing responsible management.

SK Biopharm is accelerating its pipeline expansion beyond its flagship epilepsy drug cenobamate, having signed a global exclusive license agreement last month for opicalmide, a new drug compound in the selective potassium channel (Kv7) activator class.


silverpaper@heraldcorp.com